From human to mouse and back: 'tumorgraft' models surge in popularity.

  • Ken Garber
  • Published 2009 in Journal of the National Cancer Institute


resistance to gemcitabine, the standard therapy for pancreatic cancer, and sensitivity to mitomycin C, a rarely used treatment. The patient — who fi rst failed gemcitabine therapy — received mitomycin C and has been in remission for more than 2 years. The trial’s principal investigator, Manuel Hidalgo , M.D., Ph.D., stressed that tumorgrafts, at present… (More)
DOI: 10.1093/jnci/djn481


  • Blog articles referencing this paper

  • Presentations referencing similar topics